Nicolas Darveau-Garneau receives 20,000 MUX options, vesting over 3 years
Rhea-AI Filing Summary
McEwen Inc. director Nicolas Darveau-Garneau was granted 20,000 stock options on 08/11/2025 with an exercise price of $10.43. The options give the right to buy common stock and are reported as held directly.
The grant vests in three equal annual installments beginning 08/11/2026 and includes an apparent expiration date of 08/11/2030. The filing lists the acquisition of 20,000 derivative securities (stock options) under the Form 4 disclosure.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine director equity grant of 20,000 options at $10.43, standard multi-year vesting.
This Form 4 reports a typical equity compensation award to a director, showing a grant of 20,000 stock options with an exercise price of $10.43. Vesting occurs in three equal annual installments starting 08/11/2026, with an apparent expiration on 08/11/2030, and is recorded as direct beneficial ownership. The disclosure is procedural and consistent with director compensation practices; the filing itself does not disclose outstanding share counts or dilution impact.
TL;DR: Compensation grant: 20,000 options, $10.43 strike, three-year vesting beginning 08/11/2026; routine structure.
The key economic terms shown are 20,000 options at a $10.43 exercise price granted on 08/11/2025. Vesting is in three equal annual installments beginning 08/11/2026, which staggers option access over time. The grant is reported as direct ownership of derivative securities and matches standard long-term incentive design for non-employee or director awards. The filing does not provide information on prior holdings or total potential dilution.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 20,000 | $0.00 | -- |
Footnotes (1)
- [object Object]